← Studies & programmes
Myelin repairPhase 1/2 study in people — safety and possible benefitAccepting participants

PRO-1562: an early study seeking participants for a possible myelin-repair drug

Published by MyelinWatch:

PRO-1562 · The registered study plans a Phase 1 part with single doses in healthy adults to assess safety and drug exposure, followed by a Phase 2a part in adults with relapsing MS and chronic optic neuropathy to examine safety and possible effects on myelin and symptoms. Myelin repair is a study objective, not a demonstrated effect.

What is the approach?

PRO-1562 is an experimental oral small molecule studied for a possible effect on myelin repair. The study measures safety, drug exposure and repair-related outcomes. Its exact molecular target is not established by the sources reviewed here; a repair effect remains a study question, not an established action.

Approach source: ClinicalTrials.gov — PRO-1562 study record ↗

What is being studied

The registered study plans a Phase 1 part with single doses in healthy adults to assess safety and drug exposure, followed by a Phase 2a part in adults with relapsing MS and chronic optic neuropathy to examine safety and possible effects on myelin and symptoms. Myelin repair is a study objective, not a demonstrated effect.

Research stage

Phase 1/2 study in people — safety and possible benefit

The current listing is open to participants.

What we know so far

On 3 November 2026, Progentos announced that the first participant has been dosed; the study is placebo-controlled, so this does not show who received PRO-1562. The company says that the drug promoted myelin repair in laboratory and animal studies. ClinicalTrials.gov lists the overall NCT07826689 study and one Adelaide, Australia site as accepting participants, with the start still estimated for October 2026 and no results posted. It is not confirmed that the later MS part is open.

What this means for patients today

This is an experimental study, not an available treatment. The registry offers an Australian contact for eligibility, but does not show benefit or access in Greece. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Treatment or approach
PRO-1562 • registered Phase 1/2a MS study
How it is intended to work
Small-molecule promotion of myelin repair
Where the study is running
One site accepting participants listed in Adelaide, Australia; no Greece site listed
Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Progentos Therapeutics — first participant dosed announcement ↗ Source: Veeva mirror of the trial description (not the primary record) ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates — newest research developments first

  1. Combined early Phase 1/2a study in people; no results postedResearch event/source date:

    PRO-1562: Progentos reports first participant dosed in an early study of a possible myelin-repair drug

    On 3 November 2026, Progentos Therapeutics announced that the first participant has been dosed in its Phase 1/2a study of PRO-1562 (NCT07826689), an experimental oral small molecule designed to repair myelin in multiple sclerosis (MS). The company did not give the dosing date or say in which part of the study this happened. It describes the Phase 1 part as placebo-controlled single rising doses in healthy adults at one site in Australia, so the announcement does not show whether that participant received PRO-1562 or placebo. The later Phase 2a part plans six months of once-monthly doses or placebo in adults with relapsing MS and chronic optic neuropathy. The company says that the drug promoted myelin repair in laboratory and animal studies; it reports no human results. The ClinicalTrials.gov record, last updated on 29 September 2026 and checked on 6 November, still shows the study as accepting participants, an estimated October 2026 start and no posted results.

    Source: Progentos Therapeutics — official company announcement ↗Source: ClinicalTrials.gov — PRO-1562, NCT07826689 ↗

  2. Registered early Phase 1/2a human study; estimated start remains October 2026Research event/source date:

    PRO-1562 study record now lists recruitment in Australia

    ClinicalTrials.gov changed the overall status of NCT07826689 to Accepting participants and lists one site accepting participants in Adelaide, Australia. PRO-1562 is an experimental oral small molecule. The combined early study plans a Phase 1 safety part in healthy adults and a later Phase 2a part in people with relapsing MS and chronic optic neuropathy to test whether the drug may support myelin repair. Repair is a study objective, not a demonstrated effect. Its recorded start is still estimated for October 2026. The status change does not establish that anyone has enrolled or received PRO-1562, or that the MS part is open. No study results are posted.

    Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Current NCT07826689 study record ↗

  3. Planned Phase 1/2a studyResearch event/source date:

    PRO-1562 registry entry outlines a planned early study

    The ClinicalTrials.gov record NCT07826689 describes a planned two-part study: single doses in healthy adults, followed by monthly doses in adults with relapsing MS and chronic optic neuropathy. The 17 September 2026 posting date and study details were available through a secondary mirror attributing them to ClinicalTrials.gov; they could not be independently checked against the primary record.

    Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Veeva mirror reporting ClinicalTrials.gov data (secondary source) ↗